DIAGNOSTIC ASSAYS FOR PROSTATE CANCER USING PSP94 AND PSA BIOMARKERS
    7.
    发明申请
    DIAGNOSTIC ASSAYS FOR PROSTATE CANCER USING PSP94 AND PSA BIOMARKERS 审中-公开
    使用PSP94和PSA生物标志物进行前列腺癌的诊断测定

    公开(公告)号:US20120021925A1

    公开(公告)日:2012-01-26

    申请号:US13144662

    申请日:2010-01-19

    摘要: The application refers to a method for diagnosing prostate cancer through the measurement of the combination of PSP94 (β-microseminoprotein) and F/T PSA biomarkers, the method using urine samples to measure PSP94 and serum samples to analyse F/T PSA. In one embodiment, the PSP94 is standardized to creatinine. Also based on the measurement of PSP94 and F/T PSA are provided methods and kits for (a) diagnosing aggressive prostate cancer; (b) differential diagnosis; and (c) diagnosing the progression of prostate cancer.

    摘要翻译: 该应用是指通过测量PSP94(&bgr。-microseminoprotein)和F / T PSA生物标志物的组合来诊断前列腺癌的方法,该方法使用尿液样品测量PSP94和血清样品以分析F / T PSA。 在一个实施方案中,PSP94被标准化为肌酸酐。 还基于PSP94和F / T PSA的测量提供了用于(a)诊断侵袭性前列腺癌的方法和试剂盒; (b)鉴别诊断; 和(c)诊断前列腺癌的进展。